Abstract
There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.
Original language | English |
---|---|
Pages (from-to) | 474-480 |
Number of pages | 7 |
Journal | International Journal of Technology Assessment in Health Care |
Volume | 36 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2020 |
Bibliographical note
Funding Information:Hwee-Lin Wee has received grants from Pfizer (Singapore), Roche (Singapore), Novartis (Singapore), and Johnson & Johnson (Singapore) to conduct research and workshops.
Funding Information:
This work was supported by an unrestricted grant from The International Decision Support Initiative (iDSI, www.idsihealth.org ) (grant number: OPP1134345), a global network of health, policy, and economic expertise, working to achieve Universal Health Coverage and the health Sustainable Development Goal (SDG 3), and which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. Ryota Nakamura was also supported by the Japan Society for the Promotion of Science KAKENHI (grant number: 18H00862). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the aforementioned funding agencies. A representative from iDSI participated in the first REASLISE working group meeting as an observer.
Publisher Copyright:
Copyright © The Author(s), 2020. Published by Cambridge University Press.
Keywords
- Asia
- Cost-effectiveness analysis
- Health technology assessment
- Real-world data
- Real-world evidence